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Abstract 
Background: Intracranial subependymomas account for 0.2 – 0.7% of central nervous system 
tumours and are classified as World Health Organisation (WHO) grade 1 tumours. They are 
typically located within the ventricular system and are detected incidentally or with symptoms of 
hydrocephalus. Due to paucity of studies exploring this tumour type, the objective was to 
determine the medium to long term outcome of intracranial subependymoma treated by surgical 
resection. 
Methods: Retrospective case note review of adults with intracranial WHO grade 1 
subependymoma diagnosed between 1990 – 2015 at the Walton Centre NHS Foundation Trust 
was undertaken. Tumour location, extent of resection (defined as gross total resection (GTR), 
sub-total resection (STR) or biopsy) and the WHO performance status at presentation and 
through follow- up were recorded. 
Results: 13 patients (7 males; 6 females) with a mean age of 47.6 years (range 33 - 58 years) and 
median follow-up of 46 months (range: 25 - 220 months).  8 patients had symptomatic tumours 
(headache, visual disturbance); 5 had incidental finding. Tumours were most commonly located 
in the 4th ventricle (n=8). Performance status scores at diagnosis were 0 (n=8) and 1 (n=5). Early 
post-operative performance status scores at 6 months were 0 (n=5) and 1 (n=8) and at last 
follow-up were 0 (n=11) and 1 (n=2). There was no evidence of tumour re-growth following 
GTR or STR. The commonest complication was hydrocephalus (n= 3). 
Conclusion: Subependymoma are indolent tumours. No patients exhibited a worsening of 
performance status at medium-to-long term follow-up and there were no tumour recurrence 
suggesting a shorter follow-up time may be sufficient. Surgical resection is indicated for 
symptomatic tumours or those without a clear imaging diagnosis. Incidental intraventricular 
subependymoma can be managed conservatively through MRI surveillance. 
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Abbreviations and acronyms 
WHO = World Health Organisation 
MRI = Magnetic Resonance Imaging 
LLV = Left lateral ventricle 
RLV = Right lateral ventricle 
STR = Sub-total resection 
GTR = Gross total resection 
KPS = Karnofsky Performance Status 
PFS = Progression free survival 
CT = Computer tomography 
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Introduction 
Subependymomas are rare, indolent neoplasms that are histologically classified as low grade 
(World Health Organisation (WHO) grade 1 [11]) and represents only 0.2 – 0.7% of all central 
nervous system tumours [8, 14, 16]. They present in both sexes and all age groups, but occur 
most frequently in the middle-aged to older individuals, typically in the fifth and sixth decade of 
life [10]. The majority of cases are asymptomatic but symptoms caused by hydrocephalus or 
spontaneous tumour haemorrhage may occur for larger tumours in the 4th, lateral and 3rd 
ventricles, septum pellucidum and less commonly, the spinal cord [1, 11, 14, 19]. Despite its 
benign nature, there are several reports of tumour recurrence and metastasis within the central 
nervous system following surgical resection [6, 9, 14].  
Compared to other intracranial tumours, there is a relative paucity of published series on 
subependymoma focusing on long term post-operative outcomes. As a result, the duration of 
follow-up required for these patients is not clear. A better understanding of the long-term 
outcomes would not only benefit patients but also reduce health care costs. The aims of this 
study were: to determine the medium to long term outcome of intracranial subependymoma 
treated by surgical resection and also, to discuss the change in paradigm of subependymoma 
management.  
Methods 
I. Study population 
Adult patients with a histological diagnosis of subependymoma (WHO grade 1) between January 
1990 – December 2015 at The Walton Centre NHS Foundation Trust were included in the study. 
Patients with cranial ependymoma, subependymal giant cell astrocytoma and spinal cord 
tumours were excluded from this study. Clinico-pathological data were obtained and analysed 
through retrospective case note review, out-patient follow up and serial Magnetic Resonance 
Imaging (MRI) scans.  
Tumour location (defined as left lateral ventricle (LLV), right lateral ventricle (RLV), 3rd or 4th 
ventricle), the surgical approach, extent of resection (defined as biopsy, sub-total resection (STR) 
or gross total resection (GTR) based on the operative notes and post-operative MRI), post-
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surgical complications and WHO performance status (Table 1) pre-surgery and till final follow 
up were assessed. 
II. Image Analysis 
Where available, pre-operative MRI studies were assessed for lesion signal intensity 
characteristics on T1 and T2 sequences relative to gray matter, binary assessment of the presence 
or absence of enhancement following administration of contrast agent, categorical assessment of 
the proportion of contrast enhancement if present (<6%, 6-33%, 34-67% and >67%; shown in 
Fig. 1) and 2-dimensional measures of maximum dimensions in 3 planes. 
III. Statistical analysis 
Descriptive statistical analysis was performed using SPSS Statistics v.22 Chicago, II. 
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Results 
I. Clinical presentation 
Thirteen patients (seven males and six females) with histologically proven intraventricular 
subependymomas were identified (clinical data summarised in Table 2). The age ranged from 33 
to 58 years (mean 47.6 years). The most common presenting symptoms were headaches (n=7) 
and blurred vision (n=5). The tumour was an incidental finding in five cases; the rationale for 
surgery was due to patient choice or diagnostic uncertainty about tumour type. Further 
breakdown of the patients with incidental findings are stated in Table 2.  
II. MRI findings 
Eight tumours were located in the 4th ventricle (61.5%), two in LLV (23.1%), two in the RLV 
(15.4%) and in one patient the tumour was present in both LLV and 3rd ventricle. Three had 
radiologic evidence of hydrocephalus at presentation. 
Pre-operative MRI scans were available for analysis in 9 patients (Table 3). T1 weighted scans 
showed low to intermediate signal intensity subependymoma and T2 weighted scans mainly 
exhibited hyperintense tumours in relation to the brain parenchyma. Contrast enhancement was 
observed in 8 of the 9 tumours; with half demonstrating minimal enhancement (<6%). No 
presence of calcification was noted in any MRI scans.   
III. Extent of resection 
For supratentorial subependymoma, all five patients underwent an interhemispheric transcallosal 
approach for GTR of the tumour. For the remaining eight patients with infraterntorial 
subependymoma (4th ventricle) a standard suboccipital craniectomy or craniotomy was used. The 
surgical approaches used were discussed at the multi-disciplinary meetings and were in 
concordance with the operating surgeon’s preference. Endoscopy was not used for any cases. In 
this group of eight cases, GTR was achieved in seven patients and STR in one patient due to 
tumour adherence to the vertebral artery. This group also included one patient who underwent a 
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GTR of the incidental subependymoma when operated for Chiari I malformation. Overall gross 
total resection was achieved in 12 patients (92.3%) and STR in one patient (7.7%).  
 
IV. Complications 
Post-operative complications included cerebral spinal fluid leak (n=1) that resolved with a period 
of temporary lumbar drainage and hydrocephalus (n=3), requiring treatment with 
ventriculoperitoneal shunt (n=2) or endoscopic third ventriculostomy (n=1). Only one of the 
three patients with post-operative hydrocephalus had pre-operative hydrocephalus. No patients 
developed a central nervous system infection or any new neurological deficits following surgery. 
One patient who was noted to have reduced cardiac output suffered from a cardiac arrest post-
operatively but recovered sufficiently to be discharged home after 3 weeks. That patient was 
noted to have memory deficit and impaired cognition that subsequently improved but did not 
return to his pre-morbid state. 
V. Performance status and clinical outcomes 
The median length of follow-up was 46 months (range: 25 - 220 months). Patients underwent 
annual MRI and clinical assessment. No patients received any adjuvant oncological therapy.  
There were no cases of tumour recurrence or re-growth in either the GTR or STR groups.  
WHO performance status score from diagnosis until last follow-up for all patients is summarised 
in Table 2. The performance status at diagnosis was 0 (n= 8) and 1 (n= 5) and at the early post-
operative period at 6 months was 0 (n= 5) and 1 (n= 8).  Four patients had a sustained decline in 
WHO performances status score from 0 to 1 at 6 months whilst one patient had an improvement 
in performances status from 1 to 0 during this time period. At last follow-up, performance status 
score was 0 (n= 11) and 1 (n= 2).  
Overall, the WHO performance status score improved in three patients (23.1%) [GTR n=3] at 
last recorded follow up compared to the performance status score at the time of diagnosis; 
whereas in ten patients (76.9%) [GTR n=8, STR n=1], it remained unchanged.  
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Two out of three patients with post-operative hydrocephalus showed an improvement in 
performance status by 12 months following treatment, the other patient exhibiting a stable 
performances status following treatment.  
 
 
Discussion 
Intraventricular subependymomas are rare tumours and most neurosurgeons will only operate on 
a small number of cases during their career. To date, there is sparse reporting of post-operative 
outcomes for patients following tumour removal due to its low incidence [1, 6, 9, 13]. Surgery 
for subependymoma is usually reserved for symptomatic individuals who usually present with 
hydrocephalus [1, 6, 9]. In our study, regardless of the extent of resection there were no cases of 
tumour recurrence and all patients had WHO performance status of 0 or 1 at last follow-up. 
Whilst Karnofsky Performance Status (KPS) measures functional outcome on a 10-point scale, it 
has largely been replaced in neuro-oncology studies with the WHO performance status. In our 
study, the WHO performance status at the latest follow-up improved in 23% (n=3) and stayed the 
same in 77% (n=10) compared to pre-operatively. Performance status was unchanged after 24 
months for all the patients and none reported worsening of performance status at their last 
outpatient appointment. In addition, no patients received additional oncological therapy and there 
were also no cases of tumour recurrence.  
In a series of 11 cases [9], good post-operative outcomes were observed with a median KPS of 
90 at last follow up (range 60 – 100) with 91% (10/11) of patients reporting a higher or 
equivalent KPS score compared to their pre-operative performance status [9]. Similar outcomes 
were reported in a series of 26 cases with 92% of patients (24/26) having KPS that were higher 
or equivalent to pre-operative values [6]. There was no tumour recurrence noted in either study 
[6, 9]. Combining the data from both series, only 4/37 patients had a worsening of performance 
status at last follow up, all of whom underwent a GTR. Whilst these data are limited, they 
suggest that STR may be a reasonable surgical option in patients where GTR is not possible 
since there was no statistically significant difference in survival based on the extent of resection 
[12, 15]. In our study, only one patient underwent STR and although there was no recurrence, it 
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is possible that with longer follow-up recurrence may yet occur. Previous studies have shown 
evidence of tumour progression 6 years following STR in one patient that was managed with a 
2nd operation without any subsequent complications at a further 7 years follow-up [9]. The 
variation in tumour behaviour and risk of recurrence suggests that long-term follow-up is needed 
for patients treated with STR.  
In contrast to these findings, tumour recurrence was reported in another series involving 43 
patients [1]. This cohort consisted of 34 patients with pure subependymoma (27 adults and 7 
children), 8 mixed with ependymoma and 1 mixed with astrocytoma. Of those with pure 
subependymoma, only 3% (1/34) experienced recurrence of their tumour [1]. Nearly 25% of this 
group of patients, mainly children, underwent STR with no reported cases of recurrence. 
Regarding tumour recurrence, this study theorised that poorly defined borders were an 
independent predictor of shorter progression free survival (PFS) with subependymoma [1] and 
may lead to tumour recurrence in patients. Despite a handful of cases across several studies, 
recurrence of subependymoma is considered a rare event [6, 8, 9, 18]. The extended follow up 
period of patients emphasises this finding – the longest follow up duration in the respective 
studies were 115 months [9] (age 48 at diagnosis) and 188 months [6] (age 44 at diagnosis) and 
one patient from our study was followed up for 220 months (aged 56 at diagnosis), none of 
whom demonstrated any evidence of tumour re-growth. These suggest a possible need for earlier 
discharge of patients, especially those with GTR and no post-operative hydrocephalus or 
ventriculoperitoneal shunts.  
Radiologically, subependymomas are typically well demarcated, non-enhancing, nodular lesions 
[12, 17] usually in the fourth ventricle [1, 9, 15]. On pre-contrast MRI studies, they are generally 
hypo or isointense to grey matter in T1 signal intensity and hyperintense on T2 modality [12, 
17]; and this was observed in our series. We noted contrast enhancement in 89% of our cohort 
which is not typical for subependymoma, but rather is more frequently seen in ependymoma [2]. 
However, the degree of enhancement was minimal, especially compared to ependymoma where 
contrast enhancement is more florid. There were too few cases in our study to undertake any 
analysis of MRI features to predict the likelihood of complete resection or to develop post-
operative hydrocephalus. In our cohort, hydrocephalus was the most common complication (n=3; 
23%) following subependymoma resection with patients requiring treatment with 
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ventriculoperitoneal shunt within 1 month (n=2) or an endoscopic third ventriculostomy (n=1). 
This rate is higher than previously reported (7%-19% [1, 6, 9]), but the patients in our cohort did 
not show any long-term clinical deterioration or consequences from their hydrocephalus and had 
a stable WHO performance status throughout follow-up (see Table 2). This highlights the 
successful treatment of hydrocephalus with relatively low morbidity [1, 6, 9]. 
Historical perspective 
Historically, the pathophysiology and natural history of subependymoma was less well 
understood and there has been a paradigm shift in the management of these tumours over time 
[16, 18]. This is exemplified in a case from our neurosurgical archives which revealed a patient 
who presented with raised intracranial pressure headache in 1979 and a cranial computer 
tomography (CT) showing a large intraventricular tumour (Fig. 2a). Diagnosis of 
subependymoma was made following craniotomy and open biopsy. Surgical resection was not 
considered due to the potential risk of morbidity and the patient was treated with craniospinal 
irradiation. The patient was discharged after 5 years follow up but re-presented to the 
neurosurgical service with headache 36 years after surgery. CT & MRI (Figures 2b &c) show no 
tumour growth or progression but revealed several radiation-induced meningiomas. Clinically, 
the patient suffered pituitary dysfunction and cognitive decline as late effects of radiotherapy. 
This case highlights the extremely indolent nature of subependymoma supporting the findings of 
this series.  
Evolved microneurosurgical techniques aided by neuronavigation ensure an efficient and safer 
approach for maximal tumour excision [5, 14]. These methods have also led to a significant 
reduction in complication rates from 23.5%-33% in the 1990’s [13, 15, 16] to 0%-15% in more 
recent surgical series [1, 4, 8, 9, 13, 18]. In hindsight, the radiation therapy received by our 
patient was injurious and is no longer part of modern management of subependymoma. In 
contrast, stereotactic radiosurgery has been used successfully for small diameter 
subependymoma [3,7] with no tumour recurrence reported in a case following fifty-four months 
of follow-up [3]. Whether this could be considered as an alternative first line treatment in 
subependymoma remains to be determined due to the lack of reported cases.      
This was a retrospective review of surgically treated cases of an uncommon intracranial tumour. 
It should be noted that only 13 patients were involved in our study which is a small sample size 
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but to our knowledge this is the only study to explore the effects of subependymoma resection on 
the WHO performance status over such a long follow-up period. Surgery is established as the 
treatment of choice for symptomatic subependymoma and medium to long-term decline in 
performance status has not been noted in our series. The imaging features in our series were 
slightly atypical for subependymomas with 8 out of 9 cases showing some contrast enhancement 
and this is likely to have contributed to the decision to offer surgery to these patients – the 
clinical concern being that these tumours could be ependymoma.  
 
 
Study limitation 
This was a single institution retrospective study that carries the inherent risks of bias. 
Nevertheless, this adds to the number of published series on subependymoma that enables the 
opportunity to perform a meta-analysis to better understand the risk of tumour recurrence and 
complication rates. A large multi-centre study is unlikely to occur in view of the extended 
follow-up required. Although we were able to derive the performance status from case notes, a 
more detailed assessment of quality of life was not available. In addition, for patients undergoing 
resection of lateral ventricle tumours, there was no formal assessment of cognitive function and 
memory which can be affected following surgery via an interhemispheric transcallosal approach. 
Nevertheless, patients had a good performance status, which supports the notion that there was 
no appreciable neurological harm.  
Conclusion 
Subependymomas are rare, benign tumours. No recurrence or deterioration in WHO performance 
status was noted during follow-up in our cohort suggesting a shorter follow-up time. Tumour 
resection is required for symptomatic tumours or where there is radiological uncertainty about 
the diagnosis and good neurological outcomes can be achieved with microneurosurgery. 
Incidental intraventricular subependymomas can be managed conservatively through MRI 
surveillance thereby avoiding the need for surgery. 
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Figures 
 
Fig. 1 Representative case examples of varying degrees of proportional contrast enhancement on 
post gadolinium contrast T1 weighted imaging 
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Fig. 2a) CT scan of lateral ventricle subependymoma (taken in 1979). More recent imaging (CT, 
2b and MRI axial T1 post gadolinium contrast, 2c) demonstrating stability of the 
subependymoma size over the long surveillance period. 
 
 
 
 
Tables 
Grade Explanation of activity 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g. light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about 
more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
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Table 1: Description of World Health Organization performance status scores 
	
	
	
	
	
	
	
	
	
	
	
	
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 
Dead 
